Home Asia Featured News : Bharat Biotech begins Phase 3 trials of Covaxin in India

Covid-19: Bharat Biotech begins Phase 3 trials of Covaxin in India

The has been registered with the clinical trials registry of India, and approved by the Controller General of India (DCGI)

Author

Date

Category

- Advertisement -

, Nov. 17 — Bharat Biotech on Monday said has begun the phase 3 clinical trials of its disease () candidate, Covaxin, in India, with 26,000 participants across 22 sites in the country.

The trial will be conducted in partnership with the Indian Council of Medical (ICMR), the Hyderabad-based drugmaker said in a statement.

“The Phase III trials will involve 26,000 volunteers across India, conducted in partnership with ICMR. is the largest clinical trial conducted for a in India. This is India’s first phase 3 efficacy study for a , and the largest phase III efficacy trial ever conducted in India,” Bharat Biotech said.

The trial has been registered with the clinical trials registry of India, and approved by the Drugs Controller General of India (DCGI).

- Advertisement -

Also Read: A tipping point in the against Covid-19

Trial volunteers will receive two intramuscular injections, about 28 days apart. “Participants will be randomly assigned to receive Covaxin or placebo. The trial is double blinded, such that the investigators, the participants and the company will not be aware of is assigned to which group. Covaxin has been evaluated in 1000 subjects in Phase I and Phase II clinical trials, with promising safety and immunogencity data,” the company statement read. Volunteers are those above the age of 18.

Covaxin, India’s indigenous , is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) bio containment facility.

Also Read: says its Covid-19 vaccine is nearly 95% effective

- Advertisement -

The development and of Covaxin marks a significant milestone for vaccinology in India for a novel vaccine. It is important for Indian companies to innovate and develop indigenous vaccines, especially during a pandemic,” said Suchitra Ella, joint managing director, Bharat Biotech.

For any query with respect to this article or any other content requirement, please contact Editor at contentservices@htlive.com

HT Digital streams Ltd

- Advertisement -
Advertisement

Popular

Parliament’s PAC to commence proceedings on land swap, AES and 1BestariNet, says chairman

KUALA LUMPUR, Nov. 18 -- The Public Accounts Committee (PAC) will commence proceedings on three new issues raised by...

Dr Mahathir wants to make Pejuang kingmaker in GE15

KUALA LUMPUR, Nov. 21 -- Tun Dr Mahathir Mohamad believes his newly-formed party Parti Pejuang Tanah Air could determine...

Joe Biden poised to name cabinet

India, Nov. 22 -- President-elect is moving quickly to fill out his administration and could name...
YouTube
LinkedIn
LinkedIn
Share
Instagram